Acetaminophen/Ibuprofen

Prescription-strength combination of acetaminophen and ibuprofen offers non-opioid treatment option and easier access for patients with mild-to-moderate acute pain AUCKLAND, New Zealand, Sept. 8, 2026 /PRNewswire/ -- Today, AFT Pharmaceuticals announced the U.S. launch of Combogesic®, a new FDA Approved, Non-Opioid, prescription-strength combination of acetaminophen and ibuprofen developed for adult patients (over age 18) for the short-term management of mild-to-moderate acute pain. This adds the US to 66 countries around the world where this product is now available. In partnership with the Mark Cuban Cost Plus Marketplace, Combogesic brings together two of the world's most well-known pain relievers. Combogesic offers a clinically proven, FDA approved combination, providing healthcare professionals with another non-opioid treatment option for appropriate patients. For one of healthcare's most common experiences, pain management can still involve unnecessary complexity. Utilizing AFT Pharmaceuticals' Qiksolv® formulation technology, Combogesic combines prescription-strength acetaminophen and ibuprofen into a single tablet. Rather than requiring patients to coordinate multiple medicines and dosing schedules, Combogesic delivers both analgesics in one treatment. Clinical studies have demonstrated the effectiveness of Combogesic in the short-term management of mild-to-moderate acute pain. "Expectations for pain management have evolved, yet the options to treat have remained limited," said Hartley Atkinson, founder and managing director of AFT Pharmaceuticals. "Rather than inventing another molecule, we asked whether we could rethink how two of the world's most well-known pain medicines could work together in a single prescription-strength product. The result is a proven formulation that gives healthcare professionals another non-opioid treatment option for appropriate patients." That philosophy extends beyond the medicine itself. Through their partnership with the Mark Cuban Cost Plus Marketplace", AFT Pharmaceuticals is pairing pharmaceutical innovation with a world class pharmaceutical distribution model intended to improve patient health and making Combogesic accessible and affordable to patients across the United States. "We should all get excited to have more prescription, non-opioid options to combat pain" said Mark Cuban, founder of Mark Cuban Cost Plus Drug Company. "We started Mark Cuban Cost Plus Marketplace because every American should have access to safe, affordable medicines as an essential part of advancing healthcare. So ultimately patients benefit when new medications are paired with access and price transparency. That's exactly what this partnership is about. We're proud to help make Combogesic available to patients across the country." As pain management continues to evolve, healthcare professionals and patients are looking for treatment options that reflect the realities of modern care. Combogesic reflects AFT Pharmaceuticals' commitment to expanding non-opioid treatment options for appropriate patients. For more information, visit Combogesic.com. IMPORTANT SAFETY INFORMATION See full prescribing information for complete boxed warning. About AFT Pharmaceuticals AFT is a growing New Zealand-based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories, which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. Our business model is to develop and in-license products for our markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-license our products to licensees and distributors in over 125 countries around the world. For more information about the company, visit our website About Mark Cuban Cost Plus Drugs The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just as important as the bottom line. Cost Plus Drugs transparently charges a standard markup on every drug it sells. The costplusdrugs.com online pharmacy launched in January 2022 now carries over 2,300 prescription products, delivered by mail to thousands of happy customers every day. Customers can also go to participating retail pharmacies to receive Cost Plus Drugs pricing through the Team Cuban Card. Cost Plus Drugs is working with health plans, managed-care organizations, PBMs, and self-insured employers to bring these same savings to benefit plans nationwide. Learn more at . IMPORTANT SAFETY INFORMATION Continued… Contraindications patients with known hypersensitivity to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients. the setting of coronary artery bypass graft (CABG) surgery. Warnings and Precautions Hepatotoxicity. COMBOGESIC® contains acetaminophen and ibuprofen. Acetaminophen has been associated with cases of acute liver failure; the risk is higher in those with underlying liver disease and in those who ingest alcohol. Use in patients with hepatic impairment is not recommended. Elevations of ALT or AST have been reported in NSAID-treated patients. Cardiovascular Thrombotic Events. To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Gastrointestinal Bleeding, Ulceration, and Perforation. NSAIDs may cause serious and sometimes fatal GI adverse events at any time and without warning. Avoid use in patients at higher risk. In concomitant use with low-dose aspirin, monitor patients more closely for evidence of GI bleeding. Hypertension. NSAIDs can lead to onset of new hypertension or worsening of pre-existing hypertension, which may contribute to the increased incidence of CV events. Heart Failure and Edema. Avoid use in patients with severe heart failure unless benefits outweigh risk. Renal Toxicity and Hyperkalemia. Use in patients with renal impairment is not recommended. Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Increases in serum potassium concentration, including hyperkalemia, have been reported. Hypersensitivity and Anaphylactic Reactions. Hypersensitivity and anaphylaxis associated with ibuprofen and acetaminophen have been reported, including life-threatening anaphylaxis associated with acetaminophen. Exacerbation of Asthma Related to Aspirin Sensitivity. Patients with asthma may have intolerance to aspirin and other NSAIDs. Serious Skin Reactions. Acetaminophen or NSAIDs may cause serious skin reactions such as exfoliative dermatitis, acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), or fixed drug eruption (FDE), generalized bullous fixed drug eruption (GBFDE), which can be fatal and may occur without warning. Discontinue the use of COMBOGESIC® at the first appearance of skin rash or any other sign of hypersensitivity. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). DRESS that may be life-threatening or fatal has been reported in patients taking NSAIDs. Fetal Toxicity: Premature Closure of Fetal Ductus Arteriosus. Avoid use of COMBOGESIC® in pregnant women at about 30 weeks gestation and later. COMBOGESIC® increases the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age. Oligohydramnios/Neonatal Renal Impairment. Use of COMBOGESIC® at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Hematologic Toxicity. Anemia has occurred in NSAID-treated patients and NSAID-treatment may increase the risk of bleeding events. Ophthalmological Effects. Blurred or diminished vision, scotomata, and/or changes in color vision have been reported with oral ibuprofen. Aseptic Meningitis. Aseptic meningitis with fever and coma has been observed in patients on oral ibuprofen. Masking of Inflammation and Fever. Activity of COMBOGESIC® in reducing inflammation, and possibly fever, may diminish signs of infections. Laboratory Monitoring. Monitor patients on long-term NSAID treatment with a CBC and a chemistry profile periodically. Adverse Reactions The most common adverse reactions (> 2%) are nausea, vomiting, headache, dizziness, somnolence, post-procedural hemorrhage, and swelling of the face. Drug Interactions Drugs That Interfere with Hemostasis. Ibuprofen and anticoagulants have a synergistic effect on bleeding. Concomitant use increases the risk of serious bleeding. Concomitant use of drugs that interfere with serotonin reuptake and an NSAID may increase the risk of bleeding. ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers. NSAIDs may diminish the antihypertensive effect of ACE inhibitors, ARBs, or Beta-Blockers. In the elderly, volume depleted, or those that have renal impairment, concomitant use with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. Diuretics. NSAIDs can reduce the natriuretic effect of loop diuretics and thiazides in some patients. Digoxin. Concomitant use of ibuprofen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. Lithium. NSAIDs produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. Methotrexate. Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity. Cyclosporine. Concomitant use of NSAIDs and cyclosporine may increase cyclosporine's nephrotoxicity. NSAIDS and Salicylates. Concomitant use with other NSAIDs or salicylates increases the risk of GI toxicity. Pemetrexed. Concomitant use of NSAIDs and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity. Indications and Usage COMBOGESIC® is indicated in adults (over age 18) for the short-term management of mild to moderate acute pain. To report an adverse event or product complaint, please contact us at [email protected] or call 01-248-631-4810. Adverse events may also be reported to the FDA directly at 1-800-FDA-1088 or . SOURCE AFT Pharmaceuticals 21% more press release views with Request a Demo

精彩内容 近日，儿科中药龙头集团健民药业提交了硫酸氨基葡萄糖胶囊的4类仿制上市申请，该产品是肌肉-骨骼系统（化+生）市场畅销药物，2025年在中国三大终端六大市场的销售额达到了9亿元。目前，健民药业暂无肌肉-骨骼系统化药或生物药获批，有望开拓新市场。 健民药业最新申报的产品情况 来源：CDE官网 硫酸氨基葡萄糖胶囊是一种天然的氨基单糖，是人体关节软骨基质合成所必需的物质，作为关节软骨保护剂，该产品可以改善关节疼痛及关节功能，修复软骨，强健关节，促进软骨基质的修复和重建，从而延缓骨关节疼痛的病理过程和疾病的进程，改善关节活动，缓解疼痛。 硫酸氨基葡萄糖胶囊的销售情况（单位：万元） 来源：米内网格局数据库 在中国三大终端六大市场（统计范围见文末），硫酸氨基葡萄糖胶囊的销售额自2023年以来一直保持快速增长态势，2025年达到了9亿元，2026年Q1增长率为14.33%，是肌肉-骨骼系统（化+生）市场内服TOP8产品，潜力依然可期。 在中国三大终端六大市场，肌肉-骨骼系统（化+生）的销售规模在2025年达到了470亿元水平，健民药业暂无该类药物获批。 健民药业在2025年6月及12月分别提交了对乙酰氨基酚布洛芬片和布洛芬混悬液的仿制上市申请，目前正在审评审批中，硫酸氨基葡萄糖胶囊是公司在该大类市场第三个报产的产品，可见公司对于这个百亿市场是志在必得。 2026年Q1健民药业在中国三大终端六大市场的大类格局 来源：米内网格局数据库 在中国三大终端六大市场，健民药业是中成药儿科用药TOP2集团（一级），该类药物为公司贡献了超过四成的业绩。2026年Q1，健民药业的中成药儿科用药TOP5产品包括了龙牡壮骨颗粒、小儿宝泰康颗粒、小儿紫贝宣肺糖浆（1.1类新药）、小儿宣肺止咳颗粒、小儿解感颗粒。 资料来源：CDE官网、米内网数据库 注：米内网《中国三大终端六大市场药品竞争格局》，统计范围：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。 免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。 本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。